Perioperative chemotherapy with Flot regimen in patients with resectable gastric or gastroesophageal junction adenocarcinoma (siewert type I-III). Experience of the N. N. Blokhin Russian Cancer Research Center

To date, gastric cancer patients still have a poor prognosis. Current endoscopic or surgical treatment modalities are radical only for early gastric cancer (T1). Curability dramatically declines as tumor invasion progresses and lymph node metastases appear. In Europe and North America, the 5-year overall survival rate of patients with stage T2-4 cancer is 20% [1]. Combination therapy for gastric cancer is being extensively studied to improve the treatment outcomes [2-6]. Currently, perioperative chemotherapy with FLOT regimen is the mainstay of resectable gastric cancer treatment in Europe. FLOT4-AIO randomized study has shown that the FLOT regimen was associated with significant increase in the median overall survival (50 versus 35 months), disease-free survival (18 versus 30 months) and R0 resection rate compared to ECF / ECX regimen. In this work we evaluated the efficacy and toxicity of perioperative FLOT regimen in patients with gastric cancer and gastroesophageal junction cancer type I-III cT4aN0M0, cT1-4N + M0, using a prospective database of patients treated at the N. N. Blokhin Russian Cancer Research Center.